Patents Assigned to Takeda Chemical Industry, Ltd.
-
Patent number: 6429296Abstract: The present invention provides a complex of human growth hormone and zinc containing human growth hormone and zinc at a molar ratio of about 1:1.6 to about 1:2.4, and a sustained-release preparation which comprises the complex of human growth hormone and zinc and a biodegradable polymer and which has a high entrapment ratio of human growth hormone and exhibits a stable sustained-release suppressing the initial burst.Type: GrantFiled: January 23, 2001Date of Patent: August 6, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yutaka Yamagata, Masafumi Misaki, Susumu Iwasa
-
Patent number: 6428813Abstract: In order to provide a composition having a long gastroduodenal residence time and exhibiting an improved efficacy, is provided a gastrointestinal mucosa-adherent composition comprising an active ingredient and a material which swells a viscogenic agent capable of being viscous with water a (e.g. curdlan and/or a low-substituted hydroxypropylcellulose etc.).Type: GrantFiled: September 10, 1999Date of Patent: August 6, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yohko Akiyama, Naoki Nagahara, Megumi Kitano, Masafumi Nakao
-
Publication number: 20020103210Abstract: A compound of the formula: 1Type: ApplicationFiled: January 11, 2002Publication date: August 1, 2002Applicant: TAKEDA CHEMICAL INDUSTRIES, LTD.Inventors: Shuichi Furuya, Toshihiro Imaeda, Satoshi Sasaki
-
Patent number: 6419961Abstract: A method of production of sustained-release microcapsules that comprises obtaining microcapsules comprising a bioactive substance that are encapsulated with a biodegradable polymer, and thermally drying the obtained microcapsules at a temperature not lower than the glass transition temperature of the biodegradable polymer for about 24 to about 120 hours to produce the sustained-release microcapsules comprising, relative to the weight of the sustaind-release microcapsule, not less than 60% (w/w) of the biodegradable polymer, possessing pharmaceutical characteristics clinically excellent in that a bioactive substance is released at constant rate over a very long period of time from just after administration with dramatically suppressed initial release of the bioactive substance in excess just after administration and with minimum remaining organic solvent.Type: GrantFiled: February 28, 2000Date of Patent: July 16, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yasutaka Igari, Shigeyuki Takada, Hiroshi Kosakai
-
Patent number: 6420415Abstract: Compounds represented by general formula (1) or salts thereof which have a matrix metalloprotease inhibitory activity and are useful as drugs, wherein the rings A and B represent each an optionally substituted homocycle or heterocycle, etc.; R1s are the same or different and each represents hydrogen, optionally substituted hydrocarbyl, acyl, etc.; X1 represents a bond, optionally substituted divalent aliphatic hydrocarbyl, etc.; X2 represents a bond, optionally substituted divalent aliphatic hydrocarbyl, —O—, etc.; Ys are the same or different represents hydrogen, optionally substituted hydrocarbyl, oxo, etc.; m is 0 or 1; n is an integer of 1 to 3; q1 is an integer of 1 to 2n+4; and q2 is an integer of 0 to 2n+3, provided that q1+q2 is 2n+4.Type: GrantFiled: March 20, 2001Date of Patent: July 16, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Toshiro Yamashita, Hiroshi Nara, Masayuki Takizawa, Koji Yoshimura
-
Patent number: 6420405Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, —O—, —S(O)m- (wherein m is 0, 1 or 2) or —N(R4)— (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.Type: GrantFiled: February 15, 2001Date of Patent: July 16, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yoshiyuki Inada, Keiji Kubo
-
Patent number: 6420375Abstract: To provide a novel compound of the formula: [wherein A1 ix a 5 or 6-membered ring which may be substituted by a group not containing a cyclic group, A2 is an aromatic ring which may be substituted, X is a divalent group, Y is a nitrogen atom or a methine group, Z is an ethenylene which may be substituted or ethynylene, R is a heterocyclic group which may be substituted, provided that 3,4-dihydro-6-[3-(1H-imidazol-1-yl)-1-propenyl]-2(1H)-quinolone and 2-[3-[5-ethyl-6-methyl-2-(benzyloxy)-3-pyridyl]-1-propenyl]benzoxazole are excluded.], or a salt thereof which has steroid C17,20-lyase inhibitory activity, and is useful for preventing and treating mammals suffering from, for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.Type: GrantFiled: August 18, 1999Date of Patent: July 16, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Tetsuya Aono, Fumio Itoh, Tomohiro Kaku, Masuo Yamaoka
-
Patent number: 6417175Abstract: A novel cephem compound of the formula: wherein R1 is a phosphono group or a group convertible to a phosphono group; R2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH2; n is 0 or 1; one of R3 and R4 is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R3 and R4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, or its ester or its salt, which has a superior anti-bacterial activity, stability, absorbability, etc., a production thereof and a pharmaceutical composition containing it, is provided.Type: GrantFiled: June 6, 2000Date of Patent: July 9, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Tomoyasu Ishikawa, Shohei Hashiguchi, Yuji Iizawa
-
Patent number: 6417213Abstract: A compound of the formula wherein R1 is H or a substituent; m is 1-3; Ar is an aromatic group which may be substituted; X is a bond or a divalent straight-chain group having 1-6 atoms which may be substituted; Y is —S—, —O—, or —N(R2)— (R2 is H or a substituent group), Z is —N═ or —C(R3)═ (R3 is H or a hydrocarbon group), ring A is a benzene ring; ring B is a 5- to 7-membered ring which may be substituted, or a salt thereof is useful for eliciting a prostaglandin I2 receptor agonistic effect.Type: GrantFiled: March 7, 2001Date of Patent: July 9, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Shigenori Ohkawa, Masaki Setoh, Zen-ichi Terashita
-
Patent number: 6414003Abstract: An anti-Helicobacter pylori agent comprising a compound represented by the formula: wherein A represents an aromatic ring group which may be substituted; R1 and R2, whether identical or not, each represent a hydrogen atom or a hydrocarbon group which may be substituted; R3 and R4, whether identical or not, each represent a hydrogen atom, a hydrocarbon group which may be substituted, an acyl group, a carbamoyl group which may be substituted, or a carboxyl group which may be esterified; or a salt thereof.Type: GrantFiled: November 9, 2000Date of Patent: July 2, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Tsuneo Kanamaru, Masafumi Nakao, Hiroyuki Tawada, Keiji Kamiyama
-
Patent number: 6413972Abstract: A compound of the formula: wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R1, R2 and R3 each is (i) H or (ii) a group bound via C, N, O or S; R4 is a group bound via C; R5 is H or a group bound via C or O; R6 is H or a group bound via C; R7 is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.Type: GrantFiled: November 14, 2000Date of Patent: July 2, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuichi Furuya, Toshihiro Imaeda, Satoshi Sasaki
-
Patent number: 6413947Abstract: This invention is to provide a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R2 is (1) an, optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof, which is useful for antagonizing MCP-1 receptor.Type: GrantFiled: September 13, 2000Date of Patent: July 2, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuru Shiraishi, Takahito Kitayoshi, Yoshio Aramaki, Susumu Honda, Tsuneo Oda
-
Patent number: 6407251Abstract: A novel process for preparing 2-chloro-5-chloromethylthiazole is provided which is suitable for industrial application. The process for preparing 2-chloro-5-chloromethylthiazole involves allowing 2-halogenoallyl isothiocyanate to react with chlorinating agent in the presence of an aromatic hydrocarbon which may have one or more substituents.Type: GrantFiled: December 7, 2001Date of Patent: June 18, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Takashi Miyazaki, Makoto Satou, Yoshihisa Inoue
-
Patent number: 6407248Abstract: &agr;-Unsaturated amines of the formula: wherein X1 and X2 are such that one is an electron-attracting group with the other being a hydrogen atom or an electron-attracting group; R1 is a group attached through a nitrogen atom; R2 is a hydrogen atom or a group attached through a carbon, nitrogen or oxygen atom; n is an integer equal to 0, 1 or 2; A is a heterocyclic group or a cyclic hydrocarbon group, and salts thereof and their agrochemical use as insecticidal and/or miticidal agents are described.Type: GrantFiled: September 17, 1992Date of Patent: June 18, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Isao Minamida, Koichi Iwanaga, Tetsuo Okauchi
-
Patent number: 6407129Abstract: A quaternized nitrogen-containing imidazol-1-yl or 1,2,4-triazol-1-yl compound wherein one of the nitrogen atoms constituting an azole ring is quaternized with a substituent capable of being eliminated in vivo and the substituent can be eliminated in vivo to be converted into an antifungal azole compound, has an improved solubility in water, can advantageously be applied to injection, has an improved internal absorption and can be expected to have a good effect for the treatment or prevention of disease.Type: GrantFiled: September 20, 1999Date of Patent: June 18, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Katsumi Itoh, Tomoyuki Kitazaki, Kenji Okonogi
-
Patent number: 6403606Abstract: There is disclosed a compound of the formula (A): wherein W is C—G or C—G′ (G is optionally esterified carboxyl; and G′ is halogen); X is oxygen, optionally oxidized sulfur or —(CH2)q—, (q is 0 to 5); R is optionally substituted amino or heterocyclic group; the ring B is optionally substituted nitrogen-containing 5- to 7-membered ring; L is hydrogen, optionally substituted hydrocarbon residue, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl provided that, when W is C—G, L is hydrogen, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted alkoxycarbonyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl; n is 0 or 1; the ring A may have a substituent. A process for producing the compound (A) and a pharmaceutical composition containing the compound (A) are also disclosed.Type: GrantFiled: February 17, 2000Date of Patent: June 11, 2002Assignee: Takeda Chemical Industries Ltd.Inventors: Takashi Sohda, Haruhiko Makino, Atsuo Baba
-
Patent number: 6403595Abstract: The present invention is to provide a compound or a salt thereof represented by the formula: wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, X′ is an optionally substituted alkylene chain, Y is an optionally substituted divalent cyclic group, X is a chemical bond or an optionally substituted alkylene chain, and Z is (1) an optionally substituted amino group, (2) an optionally substituted imidoyl group or (3) an optionally substituted nitrogen-containing heterocyclic group, or a pro-drug thereof, which have activated coagulation factor X inhibitory activity and which are useful as anti-coagulants.Type: GrantFiled: August 3, 2000Date of Patent: June 11, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroyuki Tawada, Fumio Itoh, Hiroshi Banno, Zen-ichi Terashita
-
Patent number: 6399639Abstract: An apoptosis inhibitor which comprises a compound of the formula: wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula: —CO—, —CH(OH)— or —NR3— where R3 represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R1; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof, or a compound having an insulin sensitivity enhancing activity.Type: GrantFiled: March 7, 2000Date of Patent: June 4, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Junji Matsui, Naoki Tarui, Yu Momose, Ken-ichi Naruo
-
Patent number: 6399316Abstract: This invention discloses a PACAP receptor protein or a salt thereof, a DNA comprising a DNA fragment coding for the protein, a method for preparing the protein, antibody against the protein, and use of the protein, DNA, and antibodies. A PACAP receptor protein was purified from the bovine cerebrum. DNAs coding for PACAP receptor proteins were isolated from bovine, rat and human cDNA libraries, and their nucleotide sequences were determined. Further, amino acid sequences deduced from the nucleotide sequences were determined.Type: GrantFiled: November 30, 1998Date of Patent: June 4, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Haruo Onda, Tetsuya Ohtaki, Yasushi Masuda, Chieko Kitada, Yoshihiro Ishibashi, Masaki Hosoya, Kazuhiro Ogi, Yasunori Miyamoto, Yugo Habata, Norio Shimamoto
-
Patent number: 6399325Abstract: Galanin receptor proteins, production and use thereof including screening of galanin receptor agonists and antagonists are provided. Galanin receptor proteins, etc. or salts thereof, partial peptides thereof, DNAs coding for the above galanin receptor protein, processes for producing the above receptor protein, methods of screening for a galanin receptor agonist and/or antagonist or screening kits therefor, agonist and/or antagonist compounds or salts thereof obtained by the above screening method or the screening kit, pharmaceutical compositions containing the above compound or its salt, and antibodies against the above receptor protein are provided. It is allowable to efficiently screen a galanin receptor agonist or antagonist by using the galanin receptor protein, the partial peptide thereof, the galanin receptor protein-encoding DNA, the receptor protein-containing cell or its membrane fraction.Type: GrantFiled: October 11, 1995Date of Patent: June 4, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Ryo Fujii, Shoji Fukusumi, Tetsuya Ohtaki, Masaki Hosoya, Kazuhiro Ohgi, Haruo Onda